Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
334.00    0.20 (0.06%)
Bid:
333.00
Ask:
333.20
Spread: 0.20 (0.06%)
Market Cap: £29.49b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Board Changes

5 Dec 2024 10:00

RNS Number : 9658O
Haleon PLC
05 December 2024
 

 

 

Haleon plc: Board Changes

 

5 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following changes to the Board.

 

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%, and in line with the Pfizer Relationship Agreement with Haleon plc, David Denton, Non-Executive Director and

representative of Pfizer Inc., stepped down from the Board on 4 December 2024.

 

Bláthnaid Bergin has been appointed as an independent Non-Executive Director and will join the Haleon Board on 24 February 2025.

 

Bláthnaid Bergin brings financial leadership and strategic planning experience from a variety of consumer-facing businesses. Bláthnaid is currently the Chief Financial Officer of J Sainsbury plc, where she has played a pivotal role in driving the company's financial strategy and operational efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior finance leadership and international positions at Aviva, RSA and GE working across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid was previously Non-Executive Director, Chair of the Audit Committee and Senior Independent Director for Artemis Alpha Investment Trust.

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Dave for his insights and contributions to the Board's discussions. We wish him all the very best for the future. I would like to welcome Bláthnaid to Haleon. With her strong track record of financial leadership and transformation from multiple consumer-facing businesses, Bláthnaid brings a wealth of relevant skills and experience to the Board."

 

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R and 6.4.8R.

 

Amanda Mellor 

Company Secretary 

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSLSUIELSEDE
Date   Source Headline
26th Feb 20255:39 pmRNSHolding(s) in Company
25th Feb 20253:00 pmRNSBoard Change
12th Feb 20253:20 pmRNSDirector/PDMR Shareholding
3rd Feb 202510:45 amRNSTotal Voting Rights
31st Jan 20253:00 pmRNSHolding(s) in Company
17th Jan 20254:30 pmRNSHolding(s) in Company
16th Jan 20254:00 pmRNSHolding(s) in Company
15th Jan 20256:00 pmRNSHaleon
15th Jan 20257:00 amRNSPRICING OF OFFERING IN HALEON PLC BY PFIZER INC.
14th Jan 20254:36 pmRNSPROPOSED OFFERING IN HALEON PLC BY PFIZER INC.
13th Jan 20252:30 pmRNSDirector/PDMR Shareholding
31st Dec 20249:00 amRNSCompletion of additional 33% stake in China JV
19th Dec 20243:00 pmRNSDirector/PDMR Shareholding
13th Dec 20244:00 pmRNSHolding(s) in Company
11th Dec 20244:00 pmRNSHolding(s) in Company
11th Dec 202412:45 pmRNSDirector/PDMR Shareholding
10th Dec 20242:15 pmRNSHolding(s) in Company
5th Dec 202410:00 amRNSBoard Changes
28th Nov 20242:30 pmRNSHolding(s) in Company
27th Nov 20244:00 pmRNSHolding(s) in Company
26th Nov 20243:00 pmRNSHolding(s) in Company
22nd Nov 20244:00 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSHolding(s) in Company
21st Nov 20243:45 pmRNSHolding(s) in Company
15th Nov 20243:45 pmRNSHolding(s) in Company
14th Nov 20243:30 pmRNSHolding(s) in Company
12th Nov 20241:00 pmRNSDirector/PDMR Shareholding
8th Nov 20244:00 pmRNSHolding(s) in Company
8th Nov 202411:00 amRNSDirector/PDMR Shareholding
6th Nov 20244:00 pmRNSHolding(s) in Company
5th Nov 20243:00 pmRNSHolding(s) in Company
4th Nov 20244:15 pmRNSHolding(s) in Company
1st Nov 202411:45 amRNSTotal Voting Rights and Capital
1st Nov 202410:00 amRNSDirector/PDMR Shareholding
31st Oct 20247:00 amRNSHaleon 2024 Q3 Trading Statement
29th Oct 20244:30 pmRNSHolding(s) in Company
18th Oct 20243:30 pmRNSHolding(s) in Company
18th Oct 202410:00 amRNSHolding(s) in Company
10th Oct 202412:15 pmRNSDirector/PDMR Shareholding
4th Oct 20244:30 pmRNSHolding(s) in Company
4th Oct 20242:30 pmRNSHolding(s) in Company
3rd Oct 202412:30 pmRNSCompletion of off-market purchase and Total Voting
3rd Oct 202410:45 amRNSDirector Declaration
1st Oct 20246:00 pmRNSHaleon
1st Oct 20247:01 amRNSUpdate on purchase alongside Pfizer offering
1st Oct 20247:00 amRNSPricing of Offering of Ordinary Shares in Haleon
30th Sep 20245:01 pmRNSProposed purchase alongside Pfizer offering
30th Sep 20244:55 pmRNSProposed Offering of Ordinary Shares in Haleon plc
30th Sep 202412:30 pmRNSTotal Voting Rights and Capital
30th Sep 202410:15 amRNSDivestment of NRT business outside US complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.